Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

• Revenue in USD (TTM)0.00
• Net income in USD-237.39m
• Incorporated2012
• Employees50.00

• Location
  Viking Therapeutics Inc9920 Pacific Heights Blvd, Suite 350SAN DIEGO 92121United StatesUSA
• Phone+1 (858) 704-4660
• Fax+1 (302) 636-5454
• Websitehttps://vikingtherapeutics.com/